2019
Liraglutide in Children and Adolescents with Type 2 Diabetes
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T. Liraglutide in Children and Adolescents with Type 2 Diabetes. New England Journal Of Medicine 2019, 381: 637-646. PMID: 31034184, DOI: 10.1056/nejmoa1903822.Peer-Reviewed Original ResearchConceptsGlycated hemoglobin levelsType 2 diabetesGastrointestinal adverse eventsAdverse eventsPlasma glucose levelsHemoglobin levelsEnd pointGlycemic controlGlucose levelsMean glycated hemoglobin levelOpen-label extension periodPrimary efficacy end pointDose of liraglutideDouble-blind periodEfficacy end pointPrimary end pointSecondary end pointsBody mass indexNumber of patientsYears of ageMetformin monotherapySubcutaneous liraglutidePlacebo groupLiraglutide groupInclusion criteriaReversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment
2017
Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes
Tamborlane WV, Polidori D, Argenti D, Di Prospero NA. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 649-655. PMID: 29271103, DOI: 10.1111/pedi.12626.Peer-Reviewed Original ResearchConceptsUrinary glucose excretionCanagliflozin 100Type 2 diabetesCanagliflozin 300T2D patientsSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsPharmacodynamics of canagliflozinSingle daily doseCotransporter 2 inhibitorsTreatment of adultsBody mass indexMaximum plasma concentrationPlasma glucose levelsDose-dependent increasePlasma concentration curveDaily doseGlucose excretionPediatric patientsMass indexPlasma concentrationsRenal thresholdGlucose levelsBody weightPatients
2009
Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system.
Cengiz E, Swan KL, Tamborlane WV, Steil GM, Steffen AT, Weinzimer SA. Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technology & Therapeutics 2009, 11: 207-10. PMID: 19344194, PMCID: PMC2842075, DOI: 10.1089/dia.2008.0102.Peer-Reviewed Original Research
2004
The Normal Glucose Tolerance Continuum in Obese Youth: Evidence for Impairment in β-Cell Function Independent of Insulin Resistance
Yeckel CW, Taksali SE, Dziura J, Weiss R, Burgert TS, Sherwin RS, Tamborlane WV, Caprio S. The Normal Glucose Tolerance Continuum in Obese Youth: Evidence for Impairment in β-Cell Function Independent of Insulin Resistance. The Journal Of Clinical Endocrinology & Metabolism 2004, 90: 747-754. PMID: 15522932, DOI: 10.1210/jc.2004-1258.Peer-Reviewed Original ResearchConceptsBeta-cell responsivenessNormal glucose tolerancePlasma glucose levelsGlucose levelsGlucose toleranceInsulin sensitivityPlasma glucoseObese youthOral glucose tolerance testType 2 diabetes mellitusDecreased insulinogenic indexGlucose tolerance continuumGlucose tolerance testInsulin sensitivity indexContinuum of riskDelta insulinInsulinogenic indexDiabetes mellitusInsulin resistancePlasma levelsTolerance testNormal rangeFunction IndependentDlGlucose concentration
1995
Enhanced adrenomedullary response and increased susceptibility to neuroglycopenia: Mechanisms underlying the adverse effects of sugar ingestion in healthy children
Jones TW, Borg WP, Boulware SD, McCarthy G, Sherwin RS, Tamborlane WV. Enhanced adrenomedullary response and increased susceptibility to neuroglycopenia: Mechanisms underlying the adverse effects of sugar ingestion in healthy children. The Journal Of Pediatrics 1995, 126: 171-177. PMID: 7844661, DOI: 10.1016/s0022-3476(95)70541-4.Peer-Reviewed Original ResearchConceptsClinical Research CenterHealthy childrenPlasma glucose concentrationAdrenomedullary responseHypoglycemic clampSymptom scoresSugar ingestionStandard oral glucose loadOral glucose loadPlasma epinephrine levelsPlasma glucose levelsGlucose concentrationCognitive effectsSugar-free drinksP300 potentialEpinephrine levelsP300 auditoryGlucose loadInsulin levelsSymptomatic responsePlasma glucoseOral administrationGlucose levelsHormone concentrationsPhysiologic mechanisms
1993
Effect of caffeine on the recognition of and responses to hypoglycemia in humans.
Kerr D, Sherwin RS, Pavalkis F, Fayad PB, Sikorski L, Rife F, Tamborlane WV, During MJ. Effect of caffeine on the recognition of and responses to hypoglycemia in humans. Annals Of Internal Medicine 1993, 119: 799-804. PMID: 8379601, DOI: 10.7326/0003-4819-119-8-199310150-00005.Peer-Reviewed Original ResearchConceptsGlucose levelsHypoglycemic symptomsCaffeine consumptionCounter-regulatory hormone levelsHyperinsulinemic glucose clamp techniqueMiddle cerebral artery velocityLarge carbohydrate loadCerebral artery velocityAcute caffeine ingestionClinical Research CenterLevels of norepinephrineAwareness of hypoglycemiaCerebral blood flowDouble-blind designGlucose clamp techniqueLate postprandial periodPlasma glucose levelsLevels of epinephrineBrain glucose useCaffeine-free colaEffects of caffeineAcute ingestionSympathoadrenal activationArtery velocityPlasma glucose